SPOCK1 contributes to the third‐generation EGFR tyrosine kinase inhibitors resistance in lung cancer

Abstract

Our study suggested that SPOCK1 could be an independent prognostic factor in NSCLC and would be a candidate for target therapy in osimertinib-resistant lung tumors.